STAT+: Experts critique flawed system for monitoring drugs’ side effects in wake of asthma drug report
STAT
JANUARY 31, 2024
and globally, for monitoring adverse reactions after a drug is on the market — one that will require extensive changes to address. Ideally, he said, the FDA should be able to both stay on top of safety concerns and avoid unnecessarily restricting access to drugs. “The question is, how safe do you want to be?”
Let's personalize your content